Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer

Cancer Science

Volumn 103, Issue 9, 2012, Pages 1617-1624

  Okabayashi, Koji ^a   Fujita, Tomonobu ^a   Miyazaki, Junichiro ^a   Okada, Tsutomu ^a   Iwata, Takashi ^a   Hirao, Nobumaru ^a   Noji, Shinobu ^a   Tsukamoto, Nobuo ^a   Goshima, Naoki ^b   Hasegawa, Hirotoshi ^a   Takeuchi, Hiroya ^a   Ueda, Masakazu ^a   Kitagawa, Yuko ^a   Kawakami, Yutaka ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BORIS ANTIGEN; CANCER TESTIS ANTIGEN; COMPLEMENTARY DNA; IMMUNOGLOBULIN G; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; DOWN REGULATION; ESOPHAGUS CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MOLECULAR CLONING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CLONING, MOLECULAR; DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865778255     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02355.x     Document Type: Article

References (44)

1. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
2. Tepper J, Krasna MJ, Niedzwiecki D et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086-92.
3. Cho Y, Miyamoto M, Kato K et al. CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 2003; 63: 1555-9.
4. Chen YT, Scanlan MJ, Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Nat Acad Sci USA 1997; 94: 1914-8.
5. Bart J, Groen HJ, van der Graaf WT et al. An oncological view on the blood-testis barrier. Lancet Oncol 2002; 3: 357-63.
6. Uenaka A, Wada H, Isobe M et al. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun 2007; 7: 9.
7. Bender A, Karbach J, Neumann A et al. LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun 2007; 7: 16.
8. Hunder NN, Wallen H, Cao J et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698-703.
9. Hirata D, Yamabuki T, Miki D et al. Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression. Clin Cancer Res 2009; 15: 256-66.
10. Ishikawa N, Takano A, Yasui W et al. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 2007; 67: 11601-11.
11. Fukunaga M. Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumours. Histopathology 2005; 46: 396-402.
12. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002; 82: 1255-7.
13. Okada T, Akada M, Fujita T et al. A novel cancer testis antigen that is frequently expressed in pancreatic, lung, and endometrial cancers. Clin Cancer Res 2006; 12: 191-7.
14. Okada T, Noji S, Goto Y et al. Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, dermatomyositis and polymyositis. Int J Cancer 2005; 116: 925-33.
15. Ishida T, Obata Y, Ohara N et al. Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity. Cancer Immun 2008; 8: 15.
16. Naora H, Montz FJ, Chai CY, Roden RB. Aberrant expression of homeobox gene HOXA7 is associated with mullerian-like differentiation of epithelial ovarian tumors and the generation of a specific autologous antibody response. Proc Nat Acad Sci USA 2001; 98: 15209-14.
17. Goshima N, Kawamura Y, Fukumoto A et al. Human protein factory for converting the transcriptome into an in vitro-expressed proteome. Nat Methods 2008; 5: 1011-7.
18. Loukinov DI, Pugacheva E, Vatolin S et al. BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Nat Acad Sci USA 2002; 99: 6806-11.
19. Voltz R, Gultekin SH, Rosenfeld MR et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 1999; 340: 1788-95.
20. Kim DU, Lee JH, Min BH et al. Risk factors of lymph node metastasis in T1 esophageal squamous cell carcinoma. J Gastroenterol Hepatol 2008; 23: 619-25.
21. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000; 232: 225-32.
22. Loukinov D, Ghochikyan A, Mkrtichyan M et al. Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem 2006; 98: 1037-43.
23. Ghochikyan A, Mkrtichyan M, Loukinov D et al. Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol 2007; 178: 566-73.
24. Mkrtichyan M, Ghochikyan A, Davtyan H et al. Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. Cell Immunol 2011; 270: 188-97.
25. D'Arcy V, Pore N, Docquier F et al. BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer 2008; 98: 571-9.
26. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun 2007; 7: 21.
27. Risinger JI, Chandramouli GV, Maxwell GL et al. Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression. Clin Cancer Res 2007; 13: 1713-9.
28. Renaud S, Pugacheva EM, Delgado MD et al. Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Res 2007; 35: 7372-88.
29. Klenova EM, Morse HC 3rd, Ohlsson R, Lobanenkov VV. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol 2002; 12: 399-414.
30. Woloszynska-Read A, Zhang W, Yu J et al. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res 2011; 17: 2170-80.
31. Kang Y, Hong JA, Chen GA, Nguyen DM, Schrump DS. Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells. Oncogene 2007; 26: 4394-403.
32. Hong JA, Kang Y, Abdullaev Z et al. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 2005; 65: 7763-74.
33. Vatolin S, Abdullaev Z, Pack SD et al. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 2005; 65: 7751-62.
34. Akcakanat A, Kanda T, Tanabe T et al. Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy. Int J Cancer 2006; 118: 123-8.
35. Fujita S, Wada H, Jungbluth AA et al. NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin Cancer Res 2004; 10: 6551-8.
36. Akcakanat A, Kanda T, Koyama Y et al. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol 2004; 54: 95-100.
37. Smith IM, Glazer CA, Mithani SK et al. Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS ONE 2009; 4: e4961.
38. Nguyen P, Cui H, Bisht KS et al. CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region. Cancer Res 2008; 68: 5546-51.
39. Lyko F, Brenton JD, Surani MA, Paro R. An imprinting element from the mouse H19 locus functions as a silencer in Drosophila. Nat Genet 1997; 16: 171-3.
40. Fedoriw AM, Stein P, Svoboda P, Schultz RM, Bartolomei MS. Transgenic RNAi reveals essential function for CTCF in H19 gene imprinting. Science 2004; 303: 238-40.
41. Kurukuti S, Tiwari VK, Tavoosidana G et al. CTCF binding at the H19 imprinting control region mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to Igf2. Proc Nat Acad Sci USA 2006; 103: 10684-9.
42. Ulaner GA, Vu TH, Li T et al. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet 2003; 12: 535-49.
43. Matouk IJ, DeGroot N, Mezan S et al. The H19 non-coding RNA is essential for human tumor growth. PLoS ONE 2007; 2: e845.
44. Hibi K, Nakamura H, Hirai A et al. Loss of H19 imprinting in esophageal cancer. Cancer Res 1996; 56: 480-2.